TSC2 and neoplasm: When evaluating tumors with a specific gene alteration frequency of > 3%, patients harboring tumor genetic alterations in TSC2, KRAS or TP53 were more likely to experience disease progression and reduced survival when compared to individuals who were WT for these specific genetic variants.